FDA’s OPDP untitled letters show rising scrutiny of DTC ads’ overall impression on consumers and urge companies to balance ...

FDA’s draft “plausible mechanism” framework gives individualized genetic therapies a clearer path to market, but questions remain, write experts at Morrison Foerster.

On this week's episode of the Business of Biotech, William Soliman, Founder and CEO of the Accreditation Council for Medical Affairs (ACMA), and Founder and CIO of White Manna Capital Partners, talks ...

As emerging biotechs scale, procurement is becoming a key lever for patient access, resilience, and long-term commercial ...

In this segment from the Life Science Leader Live event “Overcoming Operational Challenges And New Opportunities,” Dr. Ebrahim Delpassand, founder, chairman and CEO at RadioMedix, explains why ...

In this segment from the Life Science Leader Live event “Overcoming Operational Challenges And New Opportunities,” panelists talk about the importance of harmonization across regulatory agencies ...

In this segment from the Life Science Leader Live event “Overcoming Operational Challenges And New Opportunities,” Richard Valeix, CEO at Telix Therapeutics describes the on-demand requirements for ...

In this segment from the Life Science Leader Live event “Overcoming Operational Challenges And New Opportunities,” Richard Valeix, CEO at Telix Therapeutics, talks about the similarities between ...

In this segment from the Life Science Leader Live event “Overcoming Operational Challenges And New Opportunities,” our panelists talk about the synergies between diagnostics and therapeutics in ...

The global pharmaceutical supply chain has been under intense scrutiny since the COVID-19 pandemic exposed its heavy reliance on concentrated Active Pharmaceutical Ingredient (API) manufacturing hubs.

On this week's episode of the Business of Biotech, Tyler Menichiello, chief editor at Bioprocess Online, host of the Better Biopharma podcast, and my Life Science Connect (LSC) colleague, convenes the ...